AbbVie Puts Final Nail In Rova-T's Coffin After Another Trial Failure
Executive Summary
AbbVie already wrote off $4bn of the $5.8bn Stemcentrx acquisition that gave it the antibody-drug-conjugate, but now the company has ended all Rova-T development.
You may also be interested in...
AbbVie Spends $10bn On ImmunoGen To Improve Chances In ADC Space
Despite writing down $4bn after the failure of Stemcentrx’s Rova-T, AbbVie will bet big again on the cancer antibody-drug conjugate space by paying a high premium for ImmunoGen, including Elahere and its R&D potential.
Stockwatch: Repeating Past Mistakes At AbbVie
AbbVie’s latest, largest acquisition may be cast in a new light as the pandemic throws stock markets into turmoil and commercial prospects up in the air.
Ipsen, Servier Advance Lung Cancer Drug After Posting Encouraging Data
Liposomal chemotherapy drug Onivyde achieved a 44% response rate in second-line small cell lung cancer patients, providing preliminary validation of its ability to improve outcomes in the hard-to-treat disease.